JP6831176B2 - 標的治療用ライソゾーム酵素融合タンパク質およびその使用 - Google Patents

標的治療用ライソゾーム酵素融合タンパク質およびその使用 Download PDF

Info

Publication number
JP6831176B2
JP6831176B2 JP2015544209A JP2015544209A JP6831176B2 JP 6831176 B2 JP6831176 B2 JP 6831176B2 JP 2015544209 A JP2015544209 A JP 2015544209A JP 2015544209 A JP2015544209 A JP 2015544209A JP 6831176 B2 JP6831176 B2 JP 6831176B2
Authority
JP
Japan
Prior art keywords
seq
igf
amino acid
naglu
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015544209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505539A (ja
JP2016505539A5 (https=
Inventor
ミカ アオヤギ−シャーバー，
ミカ アオヤギ−シャーバー，
テレサ マーガレット クリスチャンソン，
テレサ マーガレット クリスチャンソン，
メリタ ドボラックーエウェル，
メリタ ドボラックーエウェル，
ダニエル ジェイ． ベント，
ダニエル ジェイ． ベント，
シノン ロング，
シノン ロング，
ジョナサン レボウィッツ，
ジョナサン レボウィッツ，
ダニエル ソロモン ゴールド，
ダニエル ソロモン ゴールド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of JP2016505539A publication Critical patent/JP2016505539A/ja
Publication of JP2016505539A5 publication Critical patent/JP2016505539A5/ja
Priority to JP2019136013A priority Critical patent/JP6913719B2/ja
Application granted granted Critical
Publication of JP6831176B2 publication Critical patent/JP6831176B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2015544209A 2012-11-27 2013-11-27 標的治療用ライソゾーム酵素融合タンパク質およびその使用 Active JP6831176B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019136013A JP6913719B2 (ja) 2012-11-27 2019-07-24 標的治療用ライソゾーム酵素融合タンパク質およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261730378P 2012-11-27 2012-11-27
US61/730,378 2012-11-27
US201361788968P 2013-03-15 2013-03-15
US61/788,968 2013-03-15
PCT/US2013/072287 WO2014085621A1 (en) 2012-11-27 2013-11-27 Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019136013A Division JP6913719B2 (ja) 2012-11-27 2019-07-24 標的治療用ライソゾーム酵素融合タンパク質およびその使用

Publications (3)

Publication Number Publication Date
JP2016505539A JP2016505539A (ja) 2016-02-25
JP2016505539A5 JP2016505539A5 (https=) 2017-01-12
JP6831176B2 true JP6831176B2 (ja) 2021-02-17

Family

ID=49753532

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015544209A Active JP6831176B2 (ja) 2012-11-27 2013-11-27 標的治療用ライソゾーム酵素融合タンパク質およびその使用
JP2019136013A Active JP6913719B2 (ja) 2012-11-27 2019-07-24 標的治療用ライソゾーム酵素融合タンパク質およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019136013A Active JP6913719B2 (ja) 2012-11-27 2019-07-24 標的治療用ライソゾーム酵素融合タンパク質およびその使用

Country Status (26)

Country Link
US (9) US9376480B2 (https=)
EP (2) EP2925776B1 (https=)
JP (2) JP6831176B2 (https=)
KR (4) KR102385392B1 (https=)
CN (1) CN104822701B (https=)
AR (1) AR093626A1 (https=)
AU (1) AU2013352184B2 (https=)
BR (1) BR112015012152B1 (https=)
CA (1) CA2892146A1 (https=)
CL (1) CL2015001371A1 (https=)
CY (1) CY1122555T1 (https=)
DK (2) DK2925776T3 (https=)
ES (2) ES2679374T3 (https=)
HR (2) HRP20181351T1 (https=)
HU (2) HUE039334T2 (https=)
IL (3) IL238824B (https=)
LT (1) LT3115372T (https=)
MX (2) MX377150B (https=)
PL (2) PL3115372T3 (https=)
PT (2) PT2925776T (https=)
RS (1) RS58916B1 (https=)
RU (1) RU2680581C2 (https=)
SI (1) SI3115372T1 (https=)
TW (2) TWI711632B (https=)
WO (1) WO2014085621A1 (https=)
ZA (1) ZA201503509B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170698T1 (hr) * 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
HUE039334T2 (hu) 2012-11-27 2018-12-28 Biomarin Pharm Inc Célzott terápiás lizoszómális enzim fúziós fehérjék és azok alkalmazásai
CN105377039A (zh) * 2013-05-15 2016-03-02 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
US10722559B2 (en) 2014-08-11 2020-07-28 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
US20180303877A1 (en) * 2014-09-25 2018-10-25 The General Hospital Corporation Cell-based targeted delivery of pseudonomas exotoxin
WO2016065319A1 (en) * 2014-10-24 2016-04-28 Shire Human Genetic Therapies, Inc. Lysosomal targeting of enzymes, and uses thereof
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
AU2016349528A1 (en) 2015-11-06 2018-05-17 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
EP4275751A3 (en) 2016-02-24 2023-12-27 BioMarin Pharmaceutical Inc. Improved naglu fusion protein formulation
IL305449B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous type ii diabetes
CL2016003282A1 (es) 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
FI3635009T3 (fi) 2017-06-07 2026-04-07 Regeneron Pharma Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
AU2018345303B2 (en) 2017-10-02 2025-09-18 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
MA54792A (fr) * 2018-03-09 2021-12-01 Avrobio Inc Compositions et méthodes pour le traitement de la maladie de parkinson
KR20210005154A (ko) * 2018-04-30 2021-01-13 아미쿠스 세라퓨틱스, 인코포레이티드 유전자 요법 작제물 및 사용 방법
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
EP3802619A1 (en) 2018-06-08 2021-04-14 F. Hoffmann-La Roche AG Peptidic linker with reduced post-translational modification
AR116624A1 (es) 2018-10-10 2021-05-26 Amicus Therapeutics Inc Composiciones de polipéptidos estabilizados por enlaces disulfuro y métodos de uso
WO2020102667A2 (en) * 2018-11-16 2020-05-22 Asklepios Biopharmaceutical, Inc. Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence
CN115087458A (zh) * 2019-10-10 2022-09-20 阿米库斯治疗学公司 变体igf2构建体
JP2023512423A (ja) 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
KR20240029031A (ko) 2021-06-21 2024-03-05 쥬베나 테라퓨틱스, 인크. 재생 폴리펩티드 및 이의 용도
US20240279360A1 (en) 2021-06-23 2024-08-22 Lycia Therapeutics, Inc. Bifunctional compounds containing igf-2 polypeptides
CN115975039A (zh) * 2021-10-15 2023-04-18 中山大学 重组融合抗体和抗体-药物偶联物及其用途
EP4654982A1 (en) * 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
DE10035433C2 (de) 2000-07-20 2002-07-18 Tuma Wolfgang Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003032913A2 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
CA2487815A1 (en) 2002-05-29 2003-12-11 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CN1922313B (zh) * 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
CA2600929A1 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
HRP20170698T1 (hr) * 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
US8697654B2 (en) * 2008-12-18 2014-04-15 E I Du Pont De Nemours And Company Peptide linkers for effective multivalent peptide binding
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
EP2475376B1 (en) * 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
MX362176B (es) 2010-06-25 2019-01-07 Amcor Rigid Plastics Usa Llc Sistema de depuracion de oxigeno para un recipiente.
CA2805449A1 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
US9409950B2 (en) * 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
BR112013022557A2 (pt) * 2011-03-04 2017-08-01 Shire Human Genetic Therapies ligantes de peptídeo composições de polipeptídeo e métodos para uso dos mesmos
US9409958B2 (en) * 2011-03-10 2016-08-09 Novozymes, Inc. Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
HUE039334T2 (hu) 2012-11-27 2018-12-28 Biomarin Pharm Inc Célzott terápiás lizoszómális enzim fúziós fehérjék és azok alkalmazásai

Also Published As

Publication number Publication date
WO2014085621A1 (en) 2014-06-05
US9845346B2 (en) 2017-12-19
AR093626A1 (es) 2015-06-17
TW201827468A (zh) 2018-08-01
IL262976B (en) 2020-02-27
ES2729997T3 (es) 2019-11-07
JP2019206556A (ja) 2019-12-05
ZA201503509B (en) 2016-11-30
KR102262882B1 (ko) 2021-06-10
IL262976A (en) 2018-12-31
AU2013352184A1 (en) 2015-06-04
AU2013352184B2 (en) 2018-05-31
CA2892146A1 (en) 2014-06-05
SI3115372T1 (sl) 2019-08-30
EP3115372B1 (en) 2019-03-06
DK3115372T3 (da) 2019-06-11
KR20230054482A (ko) 2023-04-24
US10301369B2 (en) 2019-05-28
IL238824B (en) 2018-11-29
US9834587B2 (en) 2017-12-05
US20190225666A1 (en) 2019-07-25
RU2680581C2 (ru) 2019-02-22
MX2019009191A (es) 2019-10-09
US20170355744A1 (en) 2017-12-14
RS58916B1 (sr) 2019-08-30
US20160031963A1 (en) 2016-02-04
TW201431884A (zh) 2014-08-16
MX377150B (es) 2025-03-07
CY1122555T1 (el) 2021-01-27
US9376480B2 (en) 2016-06-28
IL238824A0 (en) 2015-06-30
MX2015006644A (es) 2015-08-10
KR20220047892A (ko) 2022-04-19
ES2679374T3 (es) 2018-08-24
HRP20181351T1 (hr) 2018-11-02
IL272854B (en) 2021-07-29
HUE043679T2 (hu) 2019-09-30
US9771408B2 (en) 2017-09-26
KR20150088317A (ko) 2015-07-31
PL3115372T3 (pl) 2019-09-30
JP6913719B2 (ja) 2021-08-04
PT3115372T (pt) 2019-06-12
US11254725B2 (en) 2022-02-22
KR102385392B1 (ko) 2022-04-11
HK1216026A1 (en) 2016-10-07
EP2925776B1 (en) 2018-05-30
RU2015125491A (ru) 2017-01-10
CN104822701B (zh) 2018-09-21
EP2925776A1 (en) 2015-10-07
KR102521039B1 (ko) 2023-04-12
MX367024B (es) 2019-08-02
JP2016505539A (ja) 2016-02-25
DK2925776T3 (en) 2018-09-03
KR20210070389A (ko) 2021-06-14
CN104822701A (zh) 2015-08-05
US20140161788A1 (en) 2014-06-12
US20160039900A1 (en) 2016-02-11
TWI711632B (zh) 2020-12-01
TWI626250B (zh) 2018-06-11
US20160031965A1 (en) 2016-02-04
IL272854A (en) 2020-04-30
HUE039334T2 (hu) 2018-12-28
US20160031964A1 (en) 2016-02-04
US20250388644A1 (en) 2025-12-25
LT3115372T (lt) 2019-06-25
BR112015012152A2 (pt) 2017-08-15
BR112015012152B1 (pt) 2023-04-25
PT2925776T (pt) 2018-07-30
CL2015001371A1 (es) 2015-10-09
US20220127326A1 (en) 2022-04-28
PL2925776T3 (pl) 2018-11-30
HRP20190918T1 (hr) 2019-09-20
US9834588B2 (en) 2017-12-05
EP3115372A1 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
JP6913719B2 (ja) 標的治療用ライソゾーム酵素融合タンパク質およびその使用
HK1232896A1 (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1232896B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1216026B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20151008

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181016

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190326

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190724

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20190806

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190806

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200414

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20201124

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210105

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210128

R150 Certificate of patent or registration of utility model

Ref document number: 6831176

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250